REGENXBIO Total Liabilities 2014-2022 | RGNX

REGENXBIO total liabilities from 2014 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
REGENXBIO Annual Total Liabilities
(Millions of US $)
2021 $350
2020 $330
2019 $48
2018 $35
2017 $16
2016 $11
2015 $5
2014 $9
2013 $5
REGENXBIO Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $336
2021-12-31 $350
2021-09-30 $339
2021-06-30 $329
2021-03-31 $325
2020-12-31 $330
2020-09-30 $126
2020-06-30 $52
2020-03-31 $44
2019-12-31 $48
2019-09-30 $41
2019-06-30 $35
2019-03-31 $32
2018-12-31 $35
2018-09-30 $21
2018-06-30 $19
2018-03-31 $18
2017-12-31 $16
2017-09-30 $15
2017-06-30 $13
2017-03-31 $11
2016-12-31 $11
2016-09-30 $16
2016-06-30 $10
2016-03-31 $6
2015-12-31 $5
2015-09-30 $6
2015-06-30 $0
2015-03-31 $0
2014-12-31
2014-09-30 $0
2013-12-31 $5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.106B $0.470B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00